BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$68.61
Price+4.03%
$2.66
1Y
Price
Market Cap
$13.438b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-53.9%
EBITDA Margin-84.3%
Net Profit Margin-101.5%
Free Cash Flow Margin-53.9%
EBITDA Margin-84.3%
Net Profit Margin-101.5%
Free Cash Flow MarginRevenue
$579.960m
+15.5%
1y CAGR+809.0%
3y CAGR+584.8%
5y CAGREarnings
-$725.927m
+0.5%
1y CAGR-6.3%
3y CAGR-13.2%
5y CAGREPS
-$3.75
+1.1%
1y CAGR-1.1%
3y CAGR-5.3%
5y CAGRBook Value
-$2.270b
$1.371b
Assets$3.640b
Liabilities$3.385b
DebtDebt to Assets
246.9%
-5.6x
Debt to EBITDAFree Cash Flow
-$454.120m
-1.6%
1y CAGR+4.7%
3y CAGR-2.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company